GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Stock Based Compensation

Progen Co (XKRX:296160) Stock Based Compensation : ₩1,151.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Progen Co Stock Based Compensation?

Progen Co's Stock Based Compensation for the six months ended in Dec. 2024 was ₩1,151.5 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was ₩1,151.5 Mil.


Progen Co Stock Based Compensation Historical Data

The historical data trend for Progen Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progen Co Stock Based Compensation Chart

Progen Co Annual Data
Trend Dec23 Dec24
Stock Based Compensation
160.54 1,151.48

Progen Co Semi-Annual Data
Dec23 Dec24
Stock Based Compensation 160.54 1,151.48

Progen Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was ₩1,151.5 Mil.


Progen Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Progen Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Progen Co Business Description

Traded in Other Exchanges
N/A
Address
172 Magokjungang-ro, 7th Floor, Bio Innovation Park, Gangseo-gu, Seoul, KOR
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.

Progen Co Headlines

No Headlines